Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...

Zanidatamab + chemotherapy, with or without tislelizumab, may increase survival in metastatic or locally advanced gastroesophageal adenocarcinoma ...

First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...

In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line ...